<DOC>
	<DOCNO>NCT02901717</DOCNO>
	<brief_summary>This Phase 3 , multi-center , randomize , double-blind study determine efficacy safety MLT , novel antibiotic lock therapy combine minocycline edetate disodium 25 % ethanol solution . Approximately 700 subject diagnose CRBSI/CLABSI meet necessary criterion study randomize 1:1 ratio 1 2 treatment arm : - MLT Arm : MLT + SOC intravenous ( IV ) antibiotic therapy ; - Control Arm ( subject randomize Control Arm receive treatment base type virulence infect organism document Investigator prior randomization )</brief_summary>
	<brief_title>Mino-Lok Therapy ( MLT ) Treatment CRBSI/CLABSI</brief_title>
	<detailed_description>This Phase 3 , multi-center , randomize , double-blind study determine efficacy safety MLT , novel antibiotic lock therapy combine minocycline edetate disodium 25 % ethanol solution . Mino-Lok Therapy develop adjunctive therapy treatment catheter-related central line associate bloodstream infection ( CRBSI/CLABSI ) combination appropriate systemic antibiotic ( ) , preserve central venous access avoid complication morbidity associate catheter removal reinsertion . Approximately 700 subject diagnose CRBSI/CLABSI meet necessary criterion study randomize 1:1 ratio 1 2 treatment arm : - MLT Arm : MLT + SOC intravenous ( IV ) antibiotic therapy ; - Control Arm ( subject randomize Control Arm receive treatment base type virulence infect organism document Investigator prior randomization ) : 1 . Saline-heparin ( placebo ) lock + SOC IV antibiotic . ( NOTE : The saline lock arm reserve coagulase-negative staphylococci , enterococci , organism deem low virulence per Investigator ) ; 2 . Antibiotic lock + SOC IV antibiotic . The antibiotic lock comprise heparin antibiotic deliver systemically . ( NOTE : The antibiotic lock arm may include subject S. aureus , include methicillin-resistant S. aureus , vancomycin intermediate S. aureus , vancomycin-resistant S. aureus ; vancomycin resistant enterococci ; Candida , Pseudomonas ; Gram negative organism ; organism deem high virulence per Investigator ) . At least 50 subject randomize arm . In event 1 organism isolate , Investigator specify single antibiotic use lock . Randomization stratify type CVC , presence neutropenia , type virulence infect organism . The first 5 dos lock therapy administer within first 7 day follow randomization ( Visit T1 Visit T5 ) , first 3 dos administer consecutively daily ( QD ) first 3 day follow randomization ( Visit T1 Visit T3 ) . The next 2 dos administer within next 4 day . Subsequent dos occur weekly follow 2 week ( Visit T6 Visit T7 [ EOT ] ) total 7 dos . All lock treatment administer dwell time 2 hour QD day treatment . All effort make ensure lock therapy perform antibiotic dos schedule maximize time lock therapy administration IV antibiotic . The primary endpoint proportion subject ITT Population Overall Success TOC ( Week 8 ) . Success define subject demonstrate eradication pathogen , stabilization improvement sign symptom infection , catheter salvage , AND survival termination study . Analysis primary endpoint compare overall success rate MLT Arm Control Arm .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Catheter-Related Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Inpatient outpatient presence indwell CVC ( eg , totally implantable port , tunnel nontunneled catheter , peripherally inserted central catheter , hemodialysis catheter ) place 14 day onset bloodstream infection document within 96 hour prior enrollment demonstrate protocol definition CRBSI/CLABSI define : . For subject mucosal barrier injury ( MBI ) , neutropenia , graft versus host disease ( GVHD ) involve gastrointestinal ( GI ) tract , diarrhea , ONE follow must satisfy : . A recognize single pathogen culture 1 blood culture related infection another site ; OR ii . A common skin contaminant culture 2 blood culture draw consecutive calendar day ; b . For subject ( ie , subject MBI , neutropenia , GVHD involve GI tract , diarrhea ) ONE follow must satisfy : . A recognize single pathogen culture 1 blood culture related infection another site ; OR ii . A common skin contaminant culture 2 blood culture draw consecutive calendar day ; AND ONE follow present : 1 . Paired positive quantitative blood culture , whereby quantitative blood culture draw CVC peripheral vein blood culture CVC reveal least 3fold great number colony organism ( specie antibiogram ) peripherally draw quantitative blood culture ; OR 2 . A differential period CVC culture versus peripheral blood culture time positivity least 2 hour ; 2 . Subject must demonstrate least ONE follow clinical criterion ( b ) : . Temperature 38.0°C 36.0°C , 1 follow clinical sign symptom attribute CRBSI/CLABSI think related infection another site : . White blood cell count 12,000/mm3 4000/mm3 , differential count show 10 % band form ; ii . Tachycardia : Heart rate 100 bpm ; iii . Tachypnea : Respiratory rate 20 breaths/minute ; iv . Hypotension : Systolic blood pressure 90 mmHg ; OR b. Neutropenic ( ie , absolute neutrophil count 500/mm3 ) ; NOTE : A neutropenic subject without signs/symptoms may consider study least 1 positive blood culture , apparent source bacteremia , satisfy protocol definition CRBSI/CLABSI . ) ; 3 . Subjects refuse catheter remove subject , Investigator 's opinion , catheter retention duration study reasonable require ; 1 . Subjects hypersensitivity allergy tetracycline antibiotic edetate disodium ; 2 . Subjects septic shock require inotropic support unresponsive fluid resuscitation ; 3 . Subjects take disulfiram disulfiramlike drug ; 4 . Subjects prosthetic cardiac valve ; 5 . Subjects presence deepseated intravascular source infection ( eg , endocarditis [ evidence vegetation echocardiogram clinical suspicion ] septic thrombosis ) bacteremia document microbiological evidence another source infection ( eg , osteomyelitis , pneumonia , skin infection , urinary tract infection , joint infection , abdominal infection ) know due organism culture blood ; 6 . Subjects polymicrobial CRBSI/CLABSI cause pathogen would require multiple antibiotic use adequate lock therapy treatment . For example , subject MRSA Escherichia coli require treatment vancomycin meropenem would exclude study . A subject S. aureus S. epidermidis , identify pathogen could treat vancomycin , would eligible . NOTE : If 1 organism isolate , Investigator decide organisms pathogen require therapy ; 7 . Subjects presence tunnel catheter exit site infection infusion port pocket abscess manifest purulence exit site , inflammation erythema , induration 1 cm diameter ; 8 . Subjects persistent bacteremia despite 72 hour antibiotic therapy infect organism susceptible ; 9 . Subjects shortterm CVCs indwell 14 day ; 10 . Subjects central linerelated mycobacterial infection ; 11 . Subjects , opinion Investigator , high probability death within 3 month randomization due disease process CRBSI/CLABSI .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>